Hapten is generally described as a substance that is not immunogenic as such but can bind to specific antibodies (hapten-specific antibodies). A hapten may be made immunogenic by coupling it to a carrier (the immunogenic protein). The artificial antigen conjugate is then immunogenic not only to the carrier epitope but also to the hapten.
Aminoglycosides (AGs) are natural or semi-synthetic antibiotics produced by actinomycetes. They are among the first antibiotics to be introduced for clinical routine and several examples have been approved in humans. As a leading service provider of antibody construction, Creative Biolabs has extensive experience in developing polyclonal/monoclonal antibodies for small-molecule compounds. Particularly, haptens are a type of valuable but hard to solve targets for antibody preparation. Our scientists are skilled at offering the best solutions and excellent platforms for AG hapten design and synthesis, with the eventual goal of generating anti-hapten antibodies for global clients.
Comments